44) as a reducing agent. A peptidol can be obtained by means of a rapid reaction and only a simple filtering method; and the generation of by-products accompanying with the reaction can be reduced by changing conditions.
Provided is a cell having a reporter gene system of a dual-structure chromogenic enzyme, wherein the cell has the function of expressing a first chromogenic enzyme on the cell surface and releasing a second chromogenic enzyme. Further provided is a method for screening an object to be detected using the cell, comprising bringing the object to be detected into contact with the cell, and measuring a reaction signal of the chromogenic enzyme generated by the cell to analyze the characteristics of the object to be detected.
The present invention relates to an intramedullary nail screw hole positioning apparatus. The apparatus comprises: an intramedullary nail, which has a screw hole for a screw to be fastened, wherein the screw hole is used for allowing said screw to be implanted into the body or a bone of a subject, and the screw hole penetrates a tube wall of the intramedullary nail; a laser emitting source, which is used for emitting an incident light signal of laser light; an optical fiber tube, which includes a top portion, a light source optical fiber connected to the laser emitting source and used for guiding the laser light to be incident to the intramedullary nail of the subject, and a receiving optical fiber for receiving a reflected light signal reflected from the intramedullary nail of the subject, wherein the top portion of the optical fiber tube is in movable contact with the body or bone, into which the intramedullary nail is implanted, of the subject; and a receiving apparatus, which is connected to the receiving optical fiber, includes a detector and a power meter, and is used for detecting, measuring and displaying an energy difference ratio, wherein the energy difference ratio is the power ratio of the reflected light signal to the incident light signal.
A61B 90/13 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints guided by light, e.g. laser pointers
4.
TREATING SPINAL MUSCULAR ATROPHY (SMA) BY MODULATING MIR34 AND USE OF MIR34 AS A PREDICTIVE BIOMARKER OF SMA
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
CHOU, Mei-Yin (USA)
Inventor
Chen, Jun-An
Jong, Yuh-Jyh
Abstract
The present invention relates to a MiR34 as a biomarker for spinal muscular atrophy (SMA) and therapeutic/prognosis applications. In particular, the present invention provides a method for treating SMA via modulating MiR34. The present invention also provides a method for prognosis of SMA based on a baseline level of MiR34 in an SMA patient before treatment. The present invention further provides a method for predicting an SMA patient's response to treatment against SMA based on the change of a MiR34 level in the patient before and after the treatment or during the period of the treatment.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 43/00 - Drugs for specific purposes, not provided for in groups
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Yang, Ching-Chun
Chang, Chih-Hsu
Abstract
The present invention relates to a use of a composition for the manufacture of a drug for treating symptoms of a disease associated with an infection caused by hepatitis B virus (HBV), in particular a chronic HBV infection, in which the composition includes a CRM1 inhibitor, and the CRM1 inhibitor has the function of inhibiting a nuclear export pathway of HBV core particles.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A compound and the use of a pharmaceutical composition having the compound in preparation of a medicament for treating bacterial infections thereof are provided, wherein the compound is derived from AS101 and having a general formula (I) or a general formula (II).
C07D 293/02 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms not condensed with other rings
C07D 293/10 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 517/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
C07D 517/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
C08G 83/00 - Macromolecular compounds not provided for in groups
C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
8.
CLINICAL THERAPEUTIC DRUG PREDICTION AND RECOMMENDATION SYSTEM AND METHOD FOR EVALUATING EFFICACY OF SECOND-GENERATION HORMONE DRUG IN TREATMENT OF PROSTATE CANCER
A clinical therapeutic drug prediction and recommendation system (1) for evaluating the efficacy of a second-generation hormone drug in treatment of prostate cancer, comprising: an input device (10) used for receiving an ex vivo biological sample (40) and generating a physiological signal; a computer device (20) connected to the input device (10) and comprising a processor (201) used for receiving the physiological signal, said processor comprising an analysis module (2011) which compares at least the physiological signal with patient gene sets to which treatment by a first drug and a second drug are respectively applied, and then respectively obtains a first score and a second score corresponding to the first drug and the second drug by a computation method, the scores being further compared by a comparison module (2012), when the comparison result (20121) shows that the first score is greater than the second score, an indication (20131) of recommending the first drug to the individual being given, otherwise, an indication (20132) of recommending the second drug to the individual being given; and a display device, used for displaying the recommendation indication.
The present invention relates to anti-CXCR2 antibodies that recognize CXCR2 and inhibit the activity of CXCR2, and the use of the anti-CXCR2 antibodies in the treatment of pancreatic cancer and leukemia.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A method and system for predicting a stage of diabetic nephropathy by means of ophthalmoscopic images. Ophthalmoscopic images and inspection data are used in combination for establishing a prediction model for the progression of the stage of diabetic nephropathy, thereby delaying the progression of diabetic nephropathy and reducing the probability of dialysis.
A nicotinic hydrazide derivative, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The nicotinic hydrazide derivative has a molecular formula (I), wherein each of X, Y, and Z is one of N and CH, at least one of X, Y, and Z is CH, at least one of X, Y, and Z is N, and R is one of OH and NH2.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
C07B 43/00 - Formation or introduction of functional groups containing nitrogen
A positive-pressure respirator, comprising: a tube (1), provided with an inner end hole (M) and an outer end hole (N) in communication with each other, wherein the outer end hole (N) is less than the inner end hole (M), and the tube (1) is used for being inserted into a nasal cavity; and a two-way air valve (2), which is located in the tube (1), wherein the two-way air valve (2) is axially movable between the inner end hole (M) and the outer end hole (N), and the two-way air valve (2) has a fluid channel (P) in communication with the inner end hole (M) and the outer end hole (N). The positive-pressure respirator has the effects of improving sleep quality, usage comfort, aesthetics, convenience etc.
NATIONAL HEALTH RESEARCH INSTITUTES (Taiwan, Province of China)
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL (Taiwan, Province of China)
Inventor
Huang, Ming-Shyan
Wang, Chin-Chou
Wu, Chao-Chien
Zheng, Zhi-Fu
Abstract
The present invention provides a method for diagnosing asthma by using a panel of internal lipid species, including LPE 22:6, LPE 20:4, SM 16:0, PE 16:0/22:6, PE 18:0/22:6, PE 18:0/20:4 PE 18:0/18:2, and phosphatidylcholine (PC) 18:0/18:2, comprising comparing a cutoff ratio value of the panel of internal lipid species with internal lipid species ratio value for diagnosing. The present invention also provides a method for treating asthma, comprising administrating a therapeutically effective amount of a LEP 22:6 inhibitory regulator, bovine serum albumin or human serum albumin to a subject in need thereof.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Chen, Chin-Cheng
Hung, Chin-Hsien
Abstract
Provided are methods and compositions for prevention or treatment of pain, e.g., stress- related pain. Also provided is a method for producing a non-human animal model for pain, the non-human animal model produced therefrom, and a method of screening an agent pharmaceutically active in prevention or treatment of pain using such non-human animal model.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A method for preparing a slurry for photocuring 3D printing, comprising the steps of: mixing monomer molecules of a temperature-sensitive hydrogel, a photocuring initiator, a crosslinking agent, a solvent, and a ceramic material to obtain the slurry; using the slurry as a raw material, and carrying out a 3D printing procedure by a photocuring 3D printer to obtain a prototype of a 3D printed article; and oil coating the prototype of the 3D printed article, followed by heating and sintering the same, to obtain the 3D printed article.
Long non-coding DANCR (lnc-DANCR) as biomarker for the diagnosis, prognosis and monitor of cancer, including but not limited to hepatocellular carcinoma (HCC) is provided herein. In some embodiments, the method of evaluating the prognosis of hepatocellular carcinoma (HCC) in a subject comprises: isolating at least one transcript of lnc-DANCR from a biological sample of a subject; measuring the test expression level of the at least one transcript of lnc-DANCR; and evaluating the prognosis of hepatocellular carcinoma of the subject according to the comparison of the test expression level to a control expression level of the at least one transcript of lnc-DANCR. In some embodiments, a kit for evaluating the prognosis of hepatocellular carcinoma (HCC) in a subject comprises binding molecules to at least one transcript of lnc-DANCR, wherein the at least one transcript of lnc-DANCR is exosomal lnc-DANCR.
A cruciate ligament suspended internal lock fixator, which is used to solve the problem in the prior art wherein a ligament implant is prone to loosening after operation and which comprises: a hollow tube body (1) having at least one growth-inducing hole (11) and a non-return structure (14), the at least one growth-inducing hole (11) penetrating an inner wall surface (12) and an outer wall surface (13) of the hollow tube body (1), and the non-return structure (14) being located at the outer wall surface (13) of the hollow tube body (1); and a limiting member (2), which is located within the hollow tube body (1), two ends of the limiting member (2) being connected to the inner wall surface (12).
CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
CHANG GUNG UNIVERSITY (China)
KAOHSIUNG MEDICAL UNIVERSITY (China)
Inventor
Hwang, Tsong-Long
Chen, Yeh-Long
Tzeng, Cherng-Chyi
Tseng, Chih-Hua
Abstract
Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, α-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases. (I)
Disclosed are a biomedical material (1) with a synergistic effect, a manufacturing method therefor and a system comprising the biomedical material (1) with a synergistic effect. The biomedical material (1) with a synergistic effect comprises a biomedical ceramic carrier (11) with a multistage pore structure (111), wherein the biomedical ceramic carrier (11) with a synergistic effect at least contains silicon and oxygen ingredients; one nano-scaled silver particle (12) confined in the multistage pore structure (111), wherein the multistage pore structure (111) comprises one pore wall with multiple mesopores (114) and multiple large pores (112), and the pore wall separates the multiple large pores (112); and a bioactivator (13), wherein the bioactivator (13) is confined in a part of the multiple mesopores (114) or is attached to one surface of the pore wall. The biomedical material (1) is located in a system comprising microorganisms and a hydrophilic medium, and after a certain time, generates a synergistic effect and has a fractional inhibitory concentration index (FIC index) less than or equal to 0.5.
A blepharoptosis detection method and system for solving the problems that existing manual blepharoptosis detection methods are very time-consuming, and the inconsistency in measurements carried out by different doctors causing errors in measurement results. The method and system comprise: a photographing unit carrying out photography to generate an eye image; a processing unit performing image processing on the eye image to generate an edge image; the processing unit performing image computation on the eye image and the edge image to obtain multiple characteristic variables; the processing unit obtaining a characteristic parameter set according to the computation of multiple characteristic variables; and the processing unit comparing the characteristic parameter set with one piece of preset blepharoptosis information to infer the blepharoptosis severity and a levator function.
A method for preparing hyaluronic acid hydrogel microparticles and a use thereof in repairing articular cartilage defects, the method for preparing hyaluronic acid hydrogel microparticles comprising: (a) reacting hyaluronic acid with methacrylic anhydride to synthesize a methacrylated hyaluronic acid conjugate; (b) mixing the methacrylated hyaluronic acid conjugate with a photoinitiator, and irradiating ultraviolet light to carry out a photopolymerization reaction so as to obtain a hyaluronic acid hydrogel; and (c) passing the hyaluronic acid hydrogel through a sieve to obtain hyaluronic acid hydrogel microparticles.
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08J 3/28 - Treatment by wave energy or particle radiation
C08F 299/00 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
C08F 2/48 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
In the present disclosure, a new micro-ribonucleic acid has been developed by means of mice in which a glycine N-methyltransferase has been knocked out and high-throughput sequencing. The micro-ribonucleic acid can be used to assess whether an individual is at risk of suffering from liver diseases. Accordingly, also disclosed are primers and kits which can amplify the micro-ribonucleic acid by means of a polymerase chain reaction. Further disclosed is an inhibitor which can complement micro-ribonucleic acid and which acts as a pharmaceutical composition for treating liver diseases. Further disclosed is the in situ hybridization staining of a tissue section of an organ or tissue with the micro-ribonucleic acid to assess whether an individual is at risk of suffering from other cancers.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
A composite scaffold containing a drug. The scaffold comprises a porous bone material and a drug release nanocarrier, wherein the drug release nanocarrier contains a bone growth-promoting drug, and is distributed in the porous bone material. The present invention enables a local sustained release of the drug to accelerate bone regeneration at the location of a bone defect.
Provided a lycine N-methyl transferase (GNMT) mutant gene which can prevent micro RNA has-miR-244 interference related to cancers, and which then can be used for preventing or treating liver diseases, the GNMT mutant gene being selected from a sequence shown in one of the SEQ ID NOs:3-15. Also provided is recombinant vector that is formed by carrying the GNMT mutant gene in an adeno-associated virus vector, and pharmaceutical uses thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
USE OF COMPOSITION IN PREPARATION OF MEDICAMENT FOR PROMOTING INDIVIDUAL HAIR GROWTH, PREVENTING HAIR LOSS OR PROMOTING INDIVIDUAL HAIR FOLLICLE STEM CELL PRODUCTION
Disclosed in the present invention is use of a composition in the preparation of a medicament for promoting individual hair growth, preventing hair loss or promoting individual hair follicle stem cell production, the composition comprising, as a main active component, an effective amount of Derinat, which is a deoxyribonucleic acid sodium salt.
A ceramic material having the characteristics of cold isostatic pressing compression molding comprises a temperature sensing water glue and a ceramic material component. The temperature sensing water glue is combined with the ceramic material component. A method for preparing ceramics having different color levels or gradient concentrations comprises: mixing temperature sensing water glue with Zirconia ceramic powder, adding liquid salts, and increasing the stability of the mixture to a critical temperature. A gradient slurry mixing device comprises a filling tube, a top cover, a stirring member, and a material outlet end.
The present invention relates to a use of a discoidin domain receptor 1 (DDR1) inhibitor in preparing a drug for preventing or treating osteoarthritis. The present invention also relates to a use of a DDR1 activator in preparing a drug for preventing or treating a disorder related to abnormal endochondral ossification.
Disclosed in the present invention is a method for detecting a cancer or conducting cancer risk assessment, the cancer having a PREX2 manifestation of a mutation. The cancer may be a primary cancer, a metastatic cancer or a recurrent cancer. According to embodiments of the present invention, the mutation is G258V, S1113R, E1346D or K400fs. Also disclosed in the present invention is a method for treating a required individual.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
Disclosed is an arthroscopic cannula in order to solve the problem of more wounds being created due to the use of a plurality of cannulas in a conventional arthroscopic surgery. The arthroscopic cannula comprises: a cannula body (1); a spacer (2), wherein the spacer (2) is provided inside the cannula body (1), and the spacer (2) extends axially along the cannula body (1) to divide an internal space of the cannula body (1) into a first chamber (S1) and a second chamber (S2); and a joint (3) which is connected at one end of the cannula body (1), wherein the interior of the joint (3) is in communication with the first chamber (S1) and the second chamber (S2).
A61B 1/317 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
Provided in the present invention is a use for (2R, 4R)-1,2,4-trihydroxyheptadec-16-yne or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or an enantiomer in the preparation of a pharmaceutical composition for preventing or treating a hepatic injury.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
31.
METHOD FOR DETECTING WHETHER GLUCOSE METABOLISM IS ABNORMAL, AND PREVENTION AND TREATMENT THEREFOR
A method for detecting whether glucose metabolism is abnormal comprises: detecting GPx2 gene expression,GPx2 protein expression or the activity of GPx2 protein in a test body, and making comparisons with GPx2 expression amount of a normal individual, when the GPx2 expression of the individual is significantly lower than that of the normal individual, indicating that the carbohydrate metabolism of the individual is in an abnormal state. Applications of GPx2 in the preparation of a medical composition for the treatment and prevention of type II diabetes.
Disclosed is a guide for a surgical purpose (10), comprising: a long columnar body (20) which has a hollow shape, an upper side of the long columnar body (20) having a semi-cylinder (21), the bottom of the long columnar body (20) having a cuboid (22), the cuboid (22) being internally provided with an elongated slot (23) in communication from head to tail, and the interior of the semi-cylinder (21) being in communication with the interior of the cuboid (22); a wing-shaped part (30) which has a wing shape, is provided at one end of the long columnar body (20), is engaged with one side of the cuboid (22) and extends from both ends of the side, and is used for grasping during surgery; a stopper (40) which has an annular shape, is sleeved on the other side of the long columnar body (20), is engaged with the other side of the cuboid (22), and is used for pressing against tissue during surgery; and a replaceable expander (50) which is disposed in the elongated slot (23), and is used for expanding a surgical incision wherein tissues are separated.
Provided is an intraosseous implant (100), a configuration of which comprises a porous matrix (101) and a sleeve (102). Also provided is a method for implanting the intraosseous implant (100), comprising: obtaining a desired three-dimensional image of a periodontal alveolar bone defect into which the intraosseous implant (100) is to be implanted; establishing a digital three-dimensional model; according to the digital three-dimensional model, fabricating the porous matrix (101) with a configuration matching the size and the type of the periodontal alveolar bone defect to be implanted; and placing the sleeve (102) into a cavity (1013) contained in the porous matrix (101).
Disclosed is a pessary for transvaginal haemostasis, wherein the radial dimension of a balloon body (1) can be changed to form a relatively large pressure on a vaginal wall, thereby achieving the effect of high-pressure haemostasis. The pessary for transvaginal haemostasis comprises: the balloon body (1), being made of an expandable material, the balloon body (1) having a cavity (11), the cavity (11) having a filling hole (12) so that a fluid can be filled into or drawn out of the cavity (11) through the filling hole, the balloon body (1) having a first end (1a) and a second end (1b), the balloon body (1) having at least one hollow passage (13), the passage (13) running through the first end (1a) and the second end (1b) of the balloon body (1) and not being in communication with the cavity (11), an outer surface of the balloon body (1) having at least one channel (14), and the channel (14) also running through the first end (1a) and the second end (1b) of the balloon body (1); and a support body (2) having a coupling end (2a) and a support end (2b), the coupling end (2a) being coupled to the second end (1b) of the balloon body (1), the support body (2) having a through hole (21) in communication with the passage (13), and the peripheral surface of the support body (2) having at least one recessed portion (22) corresponding to the channel (14).
Provided is a device for rapidly isolating cells from tissue, comprising: a stirring and cutting member, having a rotary cutting tool, wherein same is driven by a motor so as to rotate to stir and cut tissue, and can inject digestive enzymes to accelerate decomposition of the tissue; and double-layered nested cups comprising an inner cup and an outer cup, used for accommodating and filtering solution of required cells, wherein a filter device of the inner cup screens out the required cells, and the outer cup collects the filtered solution.
A pyrazolylquinoline compound comprises: a quinolinyl group attached to a substituent R1 at the C6 position, wherein the R1 is a halogen atom; a pyrazolyl group; a first phenyl group; and a second phenyl group, wherein the C2 position of the quinolinyl group is attached to the C3 or C5 position of the pyrazolyl group. In the first case where the C2 position of the quinolinyl group is attached to the C3 position of the pyrazolyl group, the C5 position of the pyrazolyl group is attached to the C4 position of the first phenyl group. In the second case where the C2 position of the quinolinyl group is attached to the C5 position of the pyrazolyl group, the C3 position of the pyrazolyl group is attached to C4 position of the first phenyl group, and the N1 position of the pyrazolyl group is attached to the C4 position of the second phenyl group.
A data encryption and decryption system and an encryption and decryption method thereof. The system comprises a verification and key generation module (1), an encryption and decryption module (2), a deconstruction and reconstruction module (3) and a database module (4), wherein the encryption and decryption module (2) is coupled to the verification and key generation module (1), the deconstruction and reconstruction module (3) is coupled to the encryption and decryption module (2), the database module (4) is coupled to the deconstruction and reconstruction module (3), and the deconstruction and reconstruction module (3) deconstructs a complete ciphertext into a plurality of fragments of ciphertexts by using a deconstruction algorithm, and then stores the plurality of fragments of ciphertexts respectively into a plurality of sub-databases of the database module. By means of the encryption and decryption method performed by the system, the privacy and security of data can be improved.
A method for additive manufacturing of 3D-printed articles, comprising: (a) depositing one or more layers of slurry by printing using a 3D printer, the slurry comprising a composition of ceramic powder; (b) further pouring oil at the circumference of the one or more layers of slurry, the height of the poured oil being less than the height of the slurry; (c) repeating steps (a) and (b) until obtaining a body with a certain geometric shape as required; and (d) heating to sinter the body to obtain a 3D-printed article, wherein the 3d printer has a print carrier temperature of 30 to 80°C.
B29C 64/00 - Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
B29C 67/00 - Shaping techniques not covered by groups , or
C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic warePreparation thereof
39.
APPLICATION OF AVOCADO EXTRACT, AVOCADENOL B, AND (2R,4R)-1,2,4-TRIHYDROXY HEPTADEC-16-YNE, AND HEALTH FOOD COMPRISING AVOCADO EXTRACT
Disclosed is application of an avocado extract to preparation of health food or a food additive for preventing virus infection of a Flaviviridae family. The present invention also provides application of avocadenol B and (2R,4R)-1,2,4-trihydroxy heptadec-16-yne to preparation of drugs for treating or preventing virus infection of a Flaviviridae family. The present invention further provides health food for inhibiting the virus replication activity or viral inflammatory response of a Flaviviridae family, comprising an effective dose of avocado extracts serving as active ingredients and pharmaceutically acceptable carriers.
Disclosed is a composition for separating adipose tissue-derived stromal cells, comprising 0.5-8% (v/v) of a first type collagenase; 0.1-0.6% (v/v) of a trypsin; and 0.01-0.2% (v/v) of a metal ion chelating agent. Disclosed is a method of separating adipose tissue-derived stromal cells, comprising obtaining an adipose tissue; treating the adipose tissue with the above composition; centrifuging the adipose tissue; and separating the adipose tissue to obtain adipose tissue-derived stromal cells. The composition and method contribute to the future rapid separation of interstitial cells in the operating room in a short period of time, and are used in regenerative medicine.
A multi-axis load bearing and gravity center measuring device comprises a first bearing plate (2), a second bearing plate (3), a connecting plate (4) and multiple third sensing elements (5). The first bearing plate (2) further includes a first sliding element (21a, 21b) and a first pressure sensing element (22). The second bearing plate (3) further includes a second sliding element (31a, 31b) and a second pressure sensing element (32). The connecting plate (4) is connected with the first sliding element (21a, 21b), the first pressure sensing element (22), the second sliding element (31a, 31b) and the second pressure sensing element (32) respectively. The third sensing elements (5) are connected with the first bearing plate (2). The device measures the pressure change of axis X, axis Y and axis Z through the first, the second and the third sensing elements respectively to measure the load bearing, the balance degree and the gravity center. The device can replace the high unit price electronic three dimensional sensors and is convenient to maintain.
Provided are oligodeoxyribonucleotides, or locked nucleic acid (LNA) -modified, and phosphorothioated (PS) bond-modified oligonucleotides directing to anti-sense microRNA-328. Also provided is a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. Further provided is a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
43.
USE OF PHARMACEUTICAL COMPOSITION IN PREPARATION OF DRUG FOR PROMOTING CHONDROCYTE GENERATION
The present invention relates to a use of a pharmaceutical composition in the preparation of a drug for promoting chondrocyte generation, wherein the pharmaceutical composition comprises a hyaluronic acid mixture and a statin compound.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Chen, Yeh-Long
Cheng, Tian-Lu
Tzeng, Cherng-Chyi
Tseng, Chih-Hua
Cheng, Ta-Chun
Cheng, Kai-Wen
Luo, Wei-Fen
Abstract
The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
HUANG, Alice Y. (USA)
Inventor
Chen, Hui-Ting
Hsieh, Kuang-Chan
Kao, Chai-Lin
Chang, Je-Ken
Ho, Mei-Ling
Abstract
A method for treating low bone mineral density associated with osteopenia, osteoporosis, and other diseases is disclosed. The method comprises administrating a composition comprising a 3,5-dihydroxypentanoic acid derivative according to Formula I to a mammal. A compound of 3,5-dihydroxypentanoic acid derivative having a structure according to Formula I or Formula II is also disclosed.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
A composition for treating diabetes and a metabolic syndrome comprises a six-carbon unit-three carbon unit-six-carbon unit (C6-C3-C6) compound that is represented by the following formula. R1 and R2 are H, and C3 is of a single bond structure.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Cheng, Tien-Lu
Kao, Chien-Han
Chen, Bing-Mae
Su, Yu-Cheng
Tung, Hsin-Yi
Abstract
Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Lin, Chun-Ching
Lin, Liang-Tzung
Richardson, Christopher D.
Hsu, Wen-Chan
Abstract
The present invention discloses a silibinin nanoparticle comprising the compound silibinin and a hydrophilic polymer. Moreover, the silibinin nanoparticle is in form of a spherical structure with a particle size of 50 to 200 nm. The present invention also discloses a use of the silibinin nanoparticle to suppress hepatitis C virus infection and a method of treating hepatitis C, by administering the silibinin nanoparticle to a subject in need.
A01N 43/32 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with two or more hetero atoms six-membered rings
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Lu, Chi-Yu
Lee, Yi-Hsuan
Abstract
The invention discloses a method for monitoring level of paraben comprising: dissolving a sample in a solvent and obtaining a supernatant containing paraben by ultrasonic vibration and high speed centrifugation; performing a derivatization reaction between a derivatization reagent and paraben by adding the derivatization reagent into the supernatant to obtain a derivatization solution containing a tagged paraben; extracting the derivatization solution by an extractant to obtain an extract containing the tagged paraben; and ionizating the tagged paraben by a laser beam and analyzing mass-to-charge ratio of the tagged paraben by an analyzer to determine molecular weight thereof.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Yu, Ming-Lung
Chuang, Wan-Long
Dai, Chia-Yen
Chou, Wen-Wen
Abstract
A method for evaluating the therapeutic efficacy of interferon(IFN)/ribavirin(RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction(PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
HUANG, Alice Y. (USA)
Inventor
Lin, Chun-Ching
Lin, Liang-Tzung
Richardson, Christopher D.
Yen, Ming-Hong
Chung, Chueh-Yao
Abstract
This invention relates to a pharmaceutical composition having saikosaponin as a main component, the use of the pharmaceutical composition, as well as the preparation method thereof, wherein the pharmaceutical composition is used to prevent or treat the infection of one virus selected from the hepatitis C virus, the measles virus, the respiratory syncytial virus, the vesicular stomatitis virus, the dengue virus, and the non-enveloped viruses.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Cheng, Tian-Lu
Chuang, Chih-Hung
Ko, Hsiu-Fen
Lu, Yun-Chi
Abstract
Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Inventor
Juo, Suh-Hang, H.
Wang, Yung-Song
Cheng, Hsin-Yun
Abstract
The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection,, stroke or ischemic stroke can be prevented and/or treated.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
HUANG, ALICE Y. (USA)
Inventor
Wu, Yang-Chang
Chang, Fang-Rong
Hsieh, Tusty-Jiuan
Du, Ying-Chi
Tsai, Yi-Hong
Hsieh, Chi-Ting
Abstract
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.
A01N 35/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
Disclosed herein are novel 4-anilinofuro[2,3-b]quinoline derivatives of formula (I), or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives and their uses in the manufacture of pharmaceutical compositions and in the treatment of cancers.
A61K 31/4738 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems
C07D 491/00 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or
57.
PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF
A series of quaternary piperazinium salts including a structure of formula (I) or (II) are provided. In formula (I) or (II), RX represents a mineral acid, an organic acid or a commercial drug containing a carboxyl moiety selected from a group consisting of the statins, the fibric acid derivatives for lowering blood lipid, the NSAIDs, the anti-asthmatic drug, the anti-diabetic drug and the prostacyclin, which can be ionically bonded with piperazine moiety. The quarternary piperazinium salts of KMUP compounds can be used as prodrugs and have multiple therapeutic functions.
C07D 473/08 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Use of leptin in enhancing the effect of medroxyprogesterone acetate on inhibition of hepatocarcinoma cells. When the level of leptin in hepatoma patients is higher, medroxyprogesterone acetate is administrated directly or combined with leptin. When the level of leptin in patients is lower, 5-hydroxy tryptophan is administrated for increasing the level of leptin, and then medroxyprogesterone acetate is administrated.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61P 35/04 - Antineoplastic agents specific for metastasis
59.
EXTRACT OF TOONA SINENSIS FROM SUPERCRITICAL FLUID EXTRACTION FOR TREATING DIABETES AND METABOLIC DISEASES, THE PREPARATION METHOD AND THE USE THEREOF
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
Alice Y. HUANG (USA)
Inventor
Lein, Pei-Jung
Sun, Chuan-Chia
Kuo, Tzu-Chen
Yang, Sheng-Chung
Wu, Yang-Chang
Chang, Fang-Rong
Hsieh, Tusty-Jiuan
Tsai, Yi-Hung
Du, Ying-Chi
Abstract
The Toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of T. sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the T. sinensis extract. This supercritical T. sinensis extract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, the T. sinensis extract further is able to be prepared as food supplement and pharmaceuticals.
A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.
patents